Also, Liang et al. predicted different HLA-A*11:01 99 restricted common neoantigens of CRC, except the positive epitope (KRAS_G12V8-16), that could be developed as the common targets for CRC immunotherapy. This evidence concerns the gene HLA-A and colorectal carcinoma.